Literature DB >> 25893457

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.

Mary-Elizabeth M Percival1, Bruno C Medeiros1, Lu Tian2, Sarah Robeson3, Ginna G Laport3, Laura J Johnston3, Judith A Shizuru3, David B Miklos3, Sally Arai3, Wen-Kai Weng3, Robert S Negrin3, Robert Lowsky3.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25893457      PMCID： PMC4489984          DOI： 10.1038/bmt.2015.62

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.

Authors:  Christoph Röllig; Martin Bornhäuser; Christian Thiede; Franziska Taube; Michael Kramer; Brigitte Mohr; Walter Aulitzky; Heinrich Bodenstein; Hans-Joachim Tischler; Reingard Stuhlmann; Ulrich Schuler; Friedrich Stölzel; Malte von Bonin; Hannes Wandt; Kerstin Schäfer-Eckart; Markus Schaich; Gerhard Ehninger
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

Review 2.  Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era.

Authors:  Frederick R Appelbaum
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

3.  Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

Authors:  Salut Brunet; Myriam Labopin; Jordi Esteve; Jan Cornelissen; Gerard Socié; Anna P Iori; Leo F Verdonck; Liisa Volin; Alois Gratwohl; Jorge Sierra; Mohamad Mohty; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

4.  Protective conditioning for acute graft-versus-host disease.

Authors:  Robert Lowsky; Tsuyoshi Takahashi; Yin Ping Liu; Sussan Dejbakhsh-Jones; F Carl Grumet; Judith A Shizuru; Ginna G Laport; Keith E Stockerl-Goldstein; Laura J Johnston; Richard T Hoppe; Daniel A Bloch; Karl G Blume; Robert S Negrin; Samuel Strober
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

5.  Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY.

Authors:  S Naik; R Wong; S Arai; J Brown; G Laport; R Lowsky; D Miklos; J Shizuru; K Blume; R Negrin; L Johnston
Journal:  Bone Marrow Transplant       Date:  2010-05-24       Impact factor: 5.483

6.  No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

Authors:  Rosemary E Gale; Robert Hills; Panagiotis D Kottaridis; Sivatharsini Srirangan; Keith Wheatley; Alan K Burnett; David C Linch
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

7.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Authors:  Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

8.  Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.

Authors:  H Joachim Deeg; Barry Storer; John T Slattery; Claudio Anasetti; Kristine C Doney; John A Hansen; Hans-Peter Kiem; Paul J Martin; Effie Petersdorf; Jerald P Radich; Jean E Sanders; Howard M Shulman; Edus H Warren; Robert P Witherspoon; Eileen M Bryant; Thomas R Chauncey; Lisa Getzendaner; Rainer Storb; Frederick R Appelbaum
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

9.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.

Authors:  Dietger Niederwieser; Michael Maris; Judith A Shizuru; Effie Petersdorf; Ute Hegenbart; Brenda M Sandmaier; David G Maloney; Barry Storer; Thoralf Lange; Thomas Chauncey; Michael Deininger; Wolfram Pönisch; Claudio Anasetti; Ann Woolfrey; Marie-Terese Little; Karl G Blume; Peter A McSweeney; Rainer F Storb
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Authors:  B C Medeiros; L Tian; S Robenson; G G Laport; L J Johnston; J A Shizuru; D B Miklos; S Arai; J E Benjamin; W-K Weng; R S Negrin; R Lowsky
Journal:  Blood Cancer J       Date:  2014-05-30       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.